Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: A multicenter observational study

Basit Öğe Kaydı
dc.authorid0000-0002-5852-3854
dc.contributor.authorÇapkın, Erhan
dc.contributor.authorYazıcı, Ali
dc.contributor.authorKarkucak, Murat
dc.contributor.authorDurmaz, Yunus
dc.contributor.authorToprak, Murat
dc.contributor.authorAtaman, Şebnem
dc.contributor.authorŞahin, Nilay
dc.contributor.authorYılmaz, Gürdal
dc.date.accessioned2023-10-05T07:58:20Z
dc.date.available2023-10-05T07:58:20Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Fizik Tedavi ve Rehabilitasyon Ana Bilim Dalı
dc.description.abstractTo evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases. When the viral serology of the patients was evaluated, 79 patients (2%) who were identified as HBs Ag positive, 486 (12%) patients who were HBs Ag negative and anti-HBc IgG positive and 20 patients (0.5%) who were anti-HCV positive. When evaluated on a disease-by-disease basis, the rate of HBsAg was found to be 2.5% in RA, 2% in AS and 0.9% in PsA. Viral reactivation was detected in 13 patients while receiving biologic agents. HBs Ag was positive in nine patients with reactivation and negative in four patients. Anti-HBc IgG, however, was positive. Six of these patients had AS, four had RA, and three had PsA. The development of hepatitis reactivation in 11.4% of HBs Ag positive patients and 0.82% of anti-HBc IgG positive patients due to the use of biologic agents is an important problem for this group of patients. Antiviral prophylaxis is recommended to be started especially in patients who are HBs Ag positive and who are using biologic agents due to viral reactivation. Therefore, it is important to carry out hepatitis screenings before biologic agent treatment and to carefully evaluate the vaccination and prophylaxis requirements.
dc.identifier.citationÇapkın, E., Yazıcı, A., Karkucak, M., Durmaz, Y., Toprak, M., Ataman, Ş. ... Yılmaz, G. (2023). Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: A multicenter observational study. Rheumatology International, 43(3), 523-531. https://doi.org/10.1007/s00296-022-05169-2
dc.identifier.doi10.1007/s00296-022-05169-2
dc.identifier.endpage531
dc.identifier.issn0172-8172
dc.identifier.issue3
dc.identifier.pmid36063169
dc.identifier.scopus2-s2.0-85137505422
dc.identifier.scopusqualityQ2
dc.identifier.startpage523
dc.identifier.urihttps://doi.org/10.1007/s00296-022-05169-2
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11525
dc.identifier.volume43
dc.identifier.wos000849991500001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorRezvani, Aylin
dc.language.isoen
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.relation.ispartofRheumatology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectHepatitis
dc.subjectInfammatory Arthritis
dc.subjectBiologic Agents
dc.subjectViral Reactivation
dc.titleEvaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: A multicenter observational study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Rezvani-Aylin-2023.pdf
Boyut:
516.65 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu